Lyndra Therapeutics Raises $101M in Series E Funding

The company intends to use the funds for the development of its pipeline, including oral weekly risperidone (LYN-005), which is near completion of a pivotal phase 3 study. Led by CEO Jessica Ballinger, Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra’s initial focus is on developing therapies in psychiatry, cardiometabolic diseases and other conditions where current approaches to treatment fail to meet patients’ needs and expectations. Its lead product candidate, oral weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. Since the founding, the company has received product funding from the Bill & Melinda Gates Foundation, the NIH, AbbVie, and Gilead Sciences, Inc.